Zhaoke Ophthalmology Ltd. Announces NMPA Acceptance of Biologics License Application for TAB014 for wAMD Treatment

Reuters

06-12

Zhaoke Ophthalmology Ltd. Announces NMPA Acceptance of Biologics License Application for TAB014 for wAMD Treatment

Zhaoke Ophthalmology Ltd. has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application $(BLA.AU)$ for TAB014, a treatment for wet age-related macular degeneration (wAMD). This marks the first submission of a bevacizumab-based antibody for wAMD in China. The application is supported by successful Phase III clinical trial results, which demonstrated the efficacy of TAB014 in improving best corrected visual acuity compared to Lucentis®. The trial was a randomized, double-blind, non-inferiority study. Zhaoke Ophthalmology Ltd. has exclusive rights over the development and commercialization of TAB014 in China, Hong Kong, and Macau, while TOT BIOPHARM Co., Ltd. will handle manufacturing. The approval process underscores Zhaoke's commitment to advancing ophthalmic treatments in the region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief on June 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542596399"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542596399\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542596399?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-12 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542596399","market":"nz","top_or_hot":-1,"title":"Zhaoke Ophthalmology Ltd. Announces NMPA Acceptance of Biologics License Application for TAB014 for wAMD Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhaoke Ophthalmology Ltd. Announces NMPA Acceptance of Biologics License Application for TAB014 for wAMD Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zhaoke Ophthalmology Ltd. has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> for TAB014, a treatment for wet age-related macular degeneration (wAMD). This marks the first submission of a bevacizumab-based antibody for wAMD in China. The application is supported by successful Phase III clinical trial results, which demonstrated the efficacy of TAB014 in improving best corrected visual acuity compared to Lucentis®. The trial was a randomized, double-blind, non-inferiority study. Zhaoke Ophthalmology Ltd. has exclusive rights over the development and commercialization of TAB014 in China, Hong Kong, and Macau, while TOT BIOPHARM Co., Ltd. will handle manufacturing. The approval process underscores Zhaoke's commitment to advancing ophthalmic treatments in the region.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology Ltd. Announces NMPA Acceptance of Biologics License Application for TAB014 for wAMD Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology Ltd. Announces NMPA Acceptance of Biologics License Application for TAB014 for wAMD Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-12 16:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhaoke Ophthalmology Ltd. Announces NMPA Acceptance of Biologics License Application for TAB014 for wAMD Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zhaoke Ophthalmology Ltd. has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> for TAB014, a treatment for wet age-related macular degeneration (wAMD). This marks the first submission of a bevacizumab-based antibody for wAMD in China. The application is supported by successful Phase III clinical trial results, which demonstrated the efficacy of TAB014 in improving best corrected visual acuity compared to Lucentis®. The trial was a randomized, double-blind, non-inferiority study. Zhaoke Ophthalmology Ltd. has exclusive rights over the development and commercialization of TAB014 in China, Hong Kong, and Macau, while TOT BIOPHARM Co., Ltd. will handle manufacturing. The approval process underscores Zhaoke's commitment to advancing ophthalmic treatments in the region.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL1YwNrn:1","article_id":"2542596399","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542596399","pubTimestamp":1749717691,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zhaoke Ophthalmology Ltd. has announced that the National Medical Products Administration  of China has accepted its Biologics License Application  for TAB014, a treatment for wet age-related macular degeneration . This marks the first submission of a bevacizumab-based antibody for wAMD in China. The application is supported by successful Phase III clinical trial results, which demonstrated the efficacy of TAB014 in improving best corrected visual acuity compared to Lucentis. The trial was a randomized, double-blind, non-inferiority study. Zhaoke Ophthalmology Ltd. has exclusive rights over the development and commercialization of TAB014 in China, Hong Kong, and Macau, while TOT BIOPHARM Co., Ltd. will handle manufacturing. The approval process underscores Zhaoke's commitment to advancing ophthalmic treatments in the region.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1191":"制药","BK1587":"次新股","BK1574":"生物医药B类股","06622":"兆科眼科-B","01875":"东曜药业-B","BK1583":"高瓴概念"},"translate_title":"兆科眼科宣布NMPA受理TAB014治疗wAMD的生物制剂许可申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01875":0.9,"06622":0.9},"content_text":"Zhaoke Ophthalmology Ltd. Announces NMPA Acceptance of Biologics License Application for TAB014 for wAMD Treatment\n    \n\n        Zhaoke Ophthalmology Ltd. has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application $(BLA.AU)$ for TAB014, a treatment for wet age-related macular degeneration (wAMD). This marks the first submission of a bevacizumab-based antibody for wAMD in China. The application is supported by successful Phase III clinical trial results, which demonstrated the efficacy of TAB014 in improving best corrected visual acuity compared to Lucentis®. The trial was a randomized, double-blind, non-inferiority study. Zhaoke Ophthalmology Ltd. has exclusive rights over the development and commercialization of TAB014 in China, Hong Kong, and Macau, while TOT BIOPHARM Co., Ltd. will handle manufacturing. The approval process underscores Zhaoke's commitment to advancing ophthalmic treatments in the region.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief on June 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}